Form 4: Incyte Principal Accounting Officer Receives Significant Equity Awards

Incyte Corp's Principal Accounting Officer, Thomas Tray, reported the acquisition of restricted stock units and employee stock options, alongside shares withheld for tax obligations.

Summary

• Thomas Tray, Principal Accounting Officer of Incyte Corp, reported several transactions.
• On July 14, 2025, 692 shares of common stock were disposed of at $69.98 per share to satisfy tax withholding obligations.
• On July 15, 2025, 583 shares of common stock were disposed of at $68.25 per share for tax withholding.
• On July 15, 2025, 4,482 restricted stock units (RSUs) were acquired at an acquisition price of $0. These RSUs will vest 25% annually over four years.
• On July 15, 2025, 3,362 employee stock options were acquired at an acquisition price of $0, with an exercise price of $68.25. These options become exercisable in 37 installments, with 25% vesting after one year and the remainder monthly over three years.
• Following these transactions, Thomas Tray beneficially owns 24,313 shares of common stock directly, including 15,166 unvested RSU shares, and 3,362 employee stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects routine executive compensation through equity grants, which aligns management incentives with shareholder interests. The dispositions are for tax purposes and are not indicative of negative sentiment.

Positives

• Grant of 4,482 restricted stock units (RSUs) to the Principal Accounting Officer, aligning management's interests with shareholder value.
• Grant of 3,362 employee stock options, providing further incentive for long-term performance.

Negatives

• Shares totaling 1,275 (692 + 583) were withheld to cover tax obligations related to previously reported restricted stock units, which is a common practice but reduces direct share ownership.

Future Outlook

The newly acquired 4,482 restricted stock units will vest 25% annually over four years. The 3,362 employee stock options will become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years, expiring on July 14, 2035.

Industry Context

This filing reflects standard executive compensation practices within the pharmaceutical or biotechnology industry, where equity awards like RSUs and stock options are common tools to incentivize long-term performance and align executive interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Employee Stock Options (ESOs) as part of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Gilead Sciences, Amgen, or Biogen.
• The vesting schedule for RSUs (25% annually over four years) is a common industry standard designed to promote long-term retention and performance.
• The vesting schedule for ESOs (25% after one year, then monthly over three years) is also typical, providing a phased incentive structure.
• The practice of withholding shares for tax obligations upon RSU settlement is a standard, non-discretionary mechanism for managing tax liabilities on equity compensation, consistent with practices observed at most publicly traded companies.

Stakeholder Impact

• Shareholders: The equity awards align the Principal Accounting Officer's financial interests with long-term shareholder value creation.
• Employees: Reflects standard compensation practices for key executives, potentially signaling stability in executive incentives.

Next Steps

• Continued vesting of 15,166 unvested restricted stock units over the coming years.
• Continued vesting of 3,362 employee stock options over the next four years.

Key Dates

Keywords

Incyte Corp, INCY, Form 4, Insider Trading, Restricted Stock Units, Employee Stock Options, Executive Compensation, Thomas Tray, Principal Accounting Officer, Equity Awards